(Q63596044)
Statements
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (English)
0 references
22 January 2019
0 references
17 September 2020
0 references
90
0 references
18 year
0 references
55 year
0 references